What is Amneal's latest dividend and current dividend yield?

What is Amneal's gross profit margin?

What is the revenue and EPS growth rate for Amneal year over year?

What is the market's earnings forecast for Amneal next quarter?

What does Amneal do and what are its main business segments?

Did Amneal beat or miss consensus estimates last quarter?

What guidance did Amneal's management provide for the next earnings period?

What factors drove the changes in Amneal's revenue and profit?

- **Q3 Growth**: $785M revenue (+12% YoY), $160M EBITDA, driven by 8% Specialty growth and 24% AvKARE expansion.
- **Key Launches**: CREXONT (80% IR prescriptions), BREKIYA (first self-administered migraine autoinjector), and 17 new Affordable Medicines products.
- **Biosimilar Momentum**: Xolair BLA filed, 6 biosimilars by 2027, and FDA guidance accelerating development timelines.
- **Financial Strength**: 9% EBITDA growth, net leverage 3.7x, and $300M+ cash flow.
- **Strategic Focus**: Vertical biosimilar integration, 20+ new product launches/year, and $500M+ peak sales potential for CREXONT.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Total revenue of $785 million (+12% YoY), with $160 million adjusted EBITDA. Specialty segment grew 8% YoY to $125 million, driven by CREXONT and UNITHROID. AvKARE (government channel) revenue increased 24% YoY to $199 million.
- **Growth Drivers**: 
  - **Specialty**: CREXONT (Parkinson's) achieved 80% prescriptions from IR patients, targeting $300-500M peak sales. BREKIYA (migraine) launched as first self-administered autoinjector for patients avoiding ER visits.
  - **Affordable Medicines**: 17 new product launches in 2025, including risperidone injectable, sodium oxybate, and Bimatoprost ophthalmic. Inhalation products (e.g., Qvar) entering pipeline for 2026+.
  - **Biosimilars**: Filed BLA for Xolair biosimilar, targeting 2027 launch with 6 biosimilars expected by 2027.
- **Pipeline Momentum**: 69 ANDAs pending (64% complex products), 44+ R&D projects (95% complex), and 20-30 new launches/year in Affordable Medicines.

**【CFO Financial Commentary】**
- **Financial Highlights**: 
  - **Revenue**: $785M (+12% YoY), with 7% YoY growth in Affordable Medicines, 11% in Specialty, and 8% in AvKARE.
  - **Margins**: Adjusted gross margin 42.7% (down 150bps YoY), but year-to-date +130bps. Adjusted EBITDA up 9% YoY to $675-685M.
  - **EPS**: $0.17 (+6% YoY), with full-year guidance raised to $0.75-0.80.
  - **Balance Sheet**: Net leverage 3.7x (down from 3.9x YoY), with $300-330M operating cash flow expected in 2025.
- **Guidance Updates**: 
  - Revenue: $3.0-3.1B (unchanged)
  - Adjusted EBITDA: $675-685M (up $10M)
  - EPS: $0.75-0.80 (up $0.05)
- **Capital Allocation**: Focus on organic growth, debt reduction (target <3x leverage), and strategic M&A in biosimilars.

**【Q&A Key Highlights】**
- **Metsera Collaboration**: Despite Pfizer and Novo bids, Amneal retains U.S. commercial rights for 18 countries. FDA draft guidance removing Phase III biosimilar studies accelerates development timelines and reduces costs, benefiting Amneal's vertically integrated biosimilar strategy.
- **Biosimilar Strategy**: Targeting 5-7 biosimilar filings/year, focusing on high-value molecules (e.g., Xolair). FDA's Part B/Part D neutral approach allows broad market access.
- **RYTARY**: Authorized generic launch with partner; no Teva generic entry expected in 2025-26.
- **DHE Autoinjector**: Addresses 132,000 migraine patients failing first-line therapies; targeting $50-100M peak sales.
- **FDA Biosimilar Guidance**: Supports Amneal's 2026+ biosimilar pipeline expansion, with 117 potential molecules vs. 30 in development industry-wide.

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

AMRX

AMRX fundamentals

You can ask Aime